Chimeric Therapeutics is trading at A$0.06, up 7.7% today, following renewed investor focus on a potential corporate transaction highlighted in its recent strategic review.
- The stock is bucking the trend of broader weakness in biotech shares, suggesting that buying interest is driven by company-specific deal speculation and restructuring hopes rather than sector momentum.
- Traders appear to be positioning for value-creating options following the strategic review, keeping the small-cap biotech in active market discussion.